Trial Profile
Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Regadenoson (Primary)
- Indications Coronary disorders
- Focus Diagnostic use
- 31 Jul 2023 Planned End Date changed from 1 Aug 2023 to 31 Aug 2024.
- 31 Jul 2023 Planned primary completion date changed from 1 Aug 2023 to 31 Aug 2024.
- 24 Feb 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.